WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018014068) ATTENUATED TYPE I IFN CD47 COMBINATION THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/014068    International Application No.:    PCT/AU2017/000151
Publication Date: 25.01.2018 International Filing Date: 19.07.2017
IPC:
A61K 38/21 (2006.01), A61K 39/395 (2006.01), C07K 16/30 (2006.01), A61P 39/00 (2006.01)
Applicants: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD [AU/AU]; Level 2, 37 Epping Road Macquarie Park, New South Wales 2113 (AU)
Inventors: POGUE, Sarah Lee; (US).
WILSON, David Scofield Jr.; (US).
TAURA, Tetsuya; (US)
Agent: DAVIES COLLISON CAVE PTY LTD; 1 Nicholson Street Melbourne, Victoria 3000 (AU)
Priority Data:
62/363,986 19.07.2016 US
Title (EN) ATTENUATED TYPE I IFN CD47 COMBINATION THERAPY
(FR) POLYTHÉRAPIE À BASE D'IFN DE TYPE I ATTÉNUÉ-CD47
Abstract: front page image
(EN)The present invention provides a combination therapy for treating a tumor in a subject. The combination therapy comprises administration of (i) an antibody which binds to a cell surface-associated antigen expressed on the tumor cell, and (ii) a polypeptide construct comprising an attenuated Type I interferon (IFN) linked to an anti-CD47 antibody. The present invention also provides a polypeptide construct comprising an attenuated Type I interferon (IFN) linked to an anti-CD47 antibody.
(FR)L'invention concerne une polythérapie destinée à traiter une tumeur chez un patient. La polythérapie selon l'invention consiste à administrer (i) un anticorps se liant à un antigène associé à la surface cellulaire exprimé sur la cellule tumorale, et (ii) une construction de polypeptide comprenant un interféron (IFN) de type I atténué lié à un anticorps anti-CD47. L'invention concerne également une construction de polypeptide comprenant un interféron (IFN) de type I atténué lié à un anticorps anti-CD47.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)